Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Highlights,Zacks Research adjusted its Q2 2025 EPS estimate for Sanofi to $0.93, slightly decreasing from a prior prediction ...

Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Sanofi now said the agreement follows completion ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Sanofi SNY reported fourth-quarter 2024 adjusted earnings of 70 cents per American depositary share, which missed the Zacks Consensus Estimate of 71 cents per share. Earnings of €1.31 per share ...

AGREEMENT BETWEEN L’ORÉAL AND SANOFI FOR THE REPURCHASEBY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L’ORÉAL Clichy, February 3, 2025 – L’Oréal announces today that it has agreed to sell ...

Sanofi said the acquisition of these shares ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlem ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...